The inhaled nitric oxide market is likely to expand rapidly over the next several years, with a CAGR of 6.64%. According to our analysis, the global inhaled nitric oxide market revenue was US$ 246.07 million in 2022 and is likely to reach US$ 426.88 million in value by 2031 as a result of its rising use in the healthcare sector to treat a range of illnesses, including cardiovascular, respiratory, and neurological disorders.
Request Sample Copy of Research Report @ https://www.astuteanalytica.com/request-sample/inhaled-nitric-oxide-market
Acute respiratory distress syndrome (ARDS), pulmonary hypertension, and other respiratory problems are all treated with inhaled nitric oxide (iNO). It functions by enabling the smooth muscles in blood vessel walls to relax, which improves blood flow and oxygenation. For instance, in the global inhaled nitric oxide industry, respiratory problems are a serious public health concern. The World Health Organisation (WHO) estimates that moderate to severe chronic obstructive pulmonary disease (COPD), one of the most common respiratory illnesses, affects 65 million people worldwide. According to a study that was published in the Lancet Respiratory Medicine Journal, the prevalence of asthma has also increased by 12% in the last ten years, affecting an estimated 334 million individuals worldwide.
Infecting more than 339 million individuals globally, asthma is one of the most prevalent respiratory illnesses. Acute asthma exacerbations are treated with inhaled nitric oxide, which can lessen the requirement for hospitalization. Additionally, it has been demonstrated that inhaled nitric oxide increases oxygenation and lowers pulmonary hypertension in COPD patients, which can enhance their quality of life. Thus, the inhaled nitric oxide industry is likely to expand.
According to a research team led by Massachusetts General Hospital (MGH), high-dose inhaled nitric oxide gas (iNO) is a safe and effective respiratory therapy for pregnant women hospitalized with severe COVID-19 pneumonia, resulting in faster weaning from supplemental oxygen and a shorter hospital stay. Researchers from four Boston hospitals found that giving pregnant women with low blood oxygenation levels twice daily nitric oxide reduced their respiratory rates without having any negative side effects, according to a study published in Obstetrics & Gynaecology.
Companies Profile
The Inhaled Nitric Oxide Market has a Huge Room for Growth and Competition, and the Top 10 Players Hold 30% of revenue.
With almost 9% of the global market’s revenue, Mallinckrodt Pharmaceuticals currently holds a commanding lead over Air Liquide Healthcare. This suggests a market that is very competitive and has a lot of participants, both big and small.
As per the top players’ market share graph, inhaled nitric oxide market leaders include Air Liquide Healthcare, Bellerophon Therapeutics, Mallinckrodt Pharmaceuticals, and Beyond Air. These businesses have been successful in establishing themselves as big participants in the market as a result of things like their effective distribution networks, their capacity for research and development, and their emphasis on product creation and innovation.
Recent Strategies Adopted by the Key Players
In January 2023, FDA approved Inhaled nitric oxide (iNO) delivery systems of the most recent generation, according to Vero Biotech. Vero Biotech of Atlanta created the third-generation Genosyl delivery device for respiratory therapists. Faster dosing, an easier workflow, and operational effectiveness are some of its new characteristics.
In September 2022, A 510(k) premarket notification application for an investigational inhaled nitric oxide delivery system for INOmax® (nitric oxide) gas has been submitted to the U.S. Food and Drug Administration (FDA), according to Mallinckrodt plc, a multinational specialty pharmaceutical business.
In April 2020, Ohio State University Wexner Medical Centre is using Nitric oxide inhalation in a new clinical trial to enhance coronavirus outcomes and keep COVID-19 patients out of intensive care, making it the first health system in Ohio to do so.
With a revenue share of around 36.8%, North America will continue to be the second-largest market for inhaled nitric oxide globally.
Inhaled nitric oxide has a sizable market in North America, which will account for more than 36.8% of global sales in 2022. Additionally, the area is a sizable producer, contributing around 35% of the world’s supply of nitric oxide for inhalation. The prevalence of several respiratory illnesses, such as acute respiratory distress syndrome (ARDS), pulmonary hypertension, and chronic obstructive pulmonary disease (COPD), is a major factor driving the need for inhaled nitric oxide in North America.
Due to the high prevalence of respiratory problems, particularly in the aging population, and the highest market for inhaled nitric oxide, respectively, the US is both the largest producer and consumer.
Due to the increased number of smokers and pollution levels, the Asia-Pacific and Europe areas are also likely to have a considerable increase in iNO demand. On the other side, the United States, Germany, and France are the top exporters of iNO, while Japan is the main importer. The price of iNO, which varies based on the location and supplier, has increased owing to the disparity between supply and demand.
To gain more insights into the market with a detailed table of content and figures, click here: https://www.astuteanalytica.com/industry-report/inhaled-nitric-oxide-market
Segmentation Analysis
The cylinder-based system is estimated to lead the market with more than 53% market share, driving the anticipated considerable growth of the worldwide inhaled nitric oxide market in the years to come. This is due to its broad use in the medical field, portability, and convenience of use, which makes it a popular option for patients with respiratory diseases.
The growing prevalence of ARDS
Acute respiratory distress syndrome (ARDS) is likely to account for more than 59% of the revenue share in terms of application. This can be due to the rise in respiratory conditions like ARDS, which can only treat with inhaled nitric oxide. Further propelling market expansion is anticipated to be the expanding understanding of the advantages of inhaled nitric oxide in the treatment of ARDS.
Hospitals are the primary consumer of inhaled nitric oxide:
With over 85% of the market share, hospitals are likely to dominate the inhaled nitric oxide market’s end-user segment. This is due to the widespread use of inhaled nitric oxide for the treatment of respiratory conditions in hospital settings and the accessibility of qualified healthcare workers who are trained to deliver the medication.
Key Players:
- Air Liquide Healthcare
- Bellerophon Therapeutics
- Beyond Air
- Circassia Pharmaceuticals
- Getinge
- International Biomedical
- LINDE
- Mallinckrodt Pharmaceuticals
- Praxair (NoxBox)
- SLE
- Vero Biotech
- Other major players
Segmentation Outline
By System
- Cylinder Based System
- Electric System
- Chemical Based System
By Type
- Adults
- Pediatrics
By Components
- Hardware
- Mechanical Ventilator
- Flow Sensor
- Respiratory Circuits Connectors
- Nitric Oxide Container
- Nitric Oxide Analyzer
- Inlet & Outlet Pipe
- Digital Monitor
- Services
- Managed Services
- Professional Services
- Consulting
- Support & Maintenance
By Applications
- Pulmonary Hypertension
- Tuberculosis Treatment
- Malaria Treatment
- Chronic Obstructive Pulmonary Application (COPD)
- Acute Respiratory Distress Syndrome (ARDS)
- Others
By End User
- Hospitals
- Clinics
- Ambulatory Centers
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Western Europe
- The UK
- Germany
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Poland
- Russia
- Rest of Eastern Europe
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
- South America
- Argentina
- Brazil
- Rest of South America
Directly Purchase a copy of report with TOC @ https://www.astuteanalytica.com/inquire-before-purchase/inhaled-nitric-oxide-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact us:
Aamir Beg
BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Email: sales@astuteanalytica.com
Website: www.astuteanalytica.com